Seres Therapeutics

Lucien Selce and MKT Capital Ltd. express concern over Seres Therapeutics allegedly rejecting a Nestlé takeover offer at $6.00-$6.50 per share, requesting the Board provide facts on their engagement with Nestlé before the VOWST sale closing on September 30th.

Graft versus Host Disease Market to grow at 9.9% CAGR (2020-2034), driven by branded therapies, strong pipeline, and increased awareness. Market size in the US was $1 billion in 2023, expected to grow at 7.4% CAGR (2024-2034). Emerging therapies like Axatilimab and CSL964 to transform market. Key companies include Equillium, Biocon, Takeda, and CSL Behring.

The graft versus host disease market is growing due to the adoption of branded therapies like JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK, a strong pipeline with over 10 new drugs expected to launch, and increased awareness of GvHD management. Innovative treatments and ongoing research aim to address unmet needs in this complex condition.

The human microbiome, crucial for health, influences metabolic functions, immunity, and disease prevention. Dysbiosis can lead to disorders, but microbiome-based treatments show promise for over 25 conditions, including infectious and autoimmune diseases. Recent FDA approvals for treatments like Rebyota® and VOWST™ highlight advancements. Research and investment in microbiome therapeutics are growing, with significant contributions from small companies and increasing interest from Big Pharma and investors.